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 About onehalf of cancer cases and two-thirds of cancer deaths occur in patients 65 years of age or older. Therefore, un-
derstanding the health status of an older patient is just as important as staging of the cancer.
 Frailty is a complex, multidimensional syndrome of increased vulnerability and loss of adaptive capacity/resistance to 
external stressors, resulting in an increased risk of adverse outcomes. Clinical presentation is non-speci!c: fatigue, un-
explained weight loss, frequent infections, decline in physical mobility/balance/gait speed. Therefore, the routine format 
of preoperative investigations often does not allow for adequate frailty identi!cation. There are two principal models of 
frailty: the phenotype model and the accumulation of de!cits model. There is no consensus on an operational de!nition 
of frailty. However, it has been demonstrated that frailty, not chronological age, is the most important risk factor for poor 
outcome. Therefore, frailty identi!cation should be obligatory before the beginning of the oncologic treatment.
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Similarly to other European countries, Poland’s population 
is aging. In early 2030s, one-third of Poland’s population will 
be aged 65 or older; in particular, the 80+ group will double. 
There also is a gender imbalance at older ages. Almost 60% of 
older adults aged 70–74 years are female and this proportion 
increases to 76% for those 90–94 years old [1]. Additionally, 
taking the oncological context into consideration, about one-
half of cancer cases and two-thirds of cancer deaths occur in 
patients 65 years of age or older [2]. As the incidence of cancer 
increases with age, the number of elderly patients with cancer 
is expected to rise markedly in the next decade. However, this 
group of patients is very heterogeneous with regard to co-mor-
bidity, physical reserve, cognitive function and social support. 
Studies report that 50% of patients over 70 years experience 
severe chemotherapy-related toxicity [3] and more than half 
have postoperative complications [4]. Therefore, identi!cation 
of patients at risk is the key element for optimal and tailored 
treatment, particularly of cancer patients [5]. 
Frailty, by de!nition, is a complex, multidimensional, trans-
itional state of increased vulnerability and loss of adaptive ca-
pacity/resistance to external stressors, resulting in an increased 
risk of adverse outcomes, both in the short and long term [5–7]. 
These external stressors comprise factors such as hospitaliza-
tion, surgery, illness (even mild one in some frail patients) or 
environmental factors. In turn, adverse outcomes associated 
with frailty include: disability, hospitalization, postoperative 
complications, functional dependence, institutionalization, 
social withdrawal and death. In the context of cancer-speci!c 
treatment, it increases the risk of chemotherapy intolerance, 
disease recurrence and progression [8]. 
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It is important to keep in mind that frailty is a concept, not 
an illness, and it is proposed to be used as a “clinical state varia-
ble”, quantifying the underlying health status of the person [6]. 
In t older adults, following a minor stressor, we observe 
a minor deterioration in function, followed by the return to 
homeostasis. In contrast, in a frail older patient a similar stres-
sor causes a signicant deterioration and, usually, without the 
return to the baseline homeostasis. This can lead to disability 
and death. Of note is that frailty is a dynamic state; in majority 
of population it will be chronic and progressing, however, in 
some patients it may be reversed to some extent [5].
The incidence of frailty is estimated to be between 10 and 
20% of patients 65 or more of age and 25–50% of patients 85+. 
However, the number depends on the assessed population 
and instruments used for it [9]. 
The etiopathogenesis of the frailty syndrome is complex 
and has not been fully understood. It is believed that a number 
of mechanisms may play a role: genetic factors, oxidative stress, 
mitochondrial dysfunction, chronic diseases that accelerate 
the development of the syndrome, lifestyle and the changes 
associated with the aging process [10]. Therefore, the frailty risk 
factors include: advanced age, polypharmacy, low physical t-
ness, cognitive disorders, malnutrition (low protein diet, decits 
of multiple vitamins), poverty and isolation [10].
Frailty syndrome may not be evident to patients, family 
members, and – what is more important – to the untrained 
clinicians. Older people, who are classied as frail, frequently 
do not identify themselves as such [11]. By denition, manife-
stations associated within a syndrome occur in combination, 
and no single manifestation is su!cient to identify those 
with the syndrome. Clinical presentation is non-specic: fa-
tigue, unexplained weight loss, frequent infections, decline 
in physical mobility, balance and gait impairment, delirium, 
"uctuating disability. Therefore, the routine format of, medical 
history, physical examination, biochemistry and imaging tests 
often do not provide the information needed for optimal 
identication of frailty. This is due that fact that it does not 
t into classic organ-specic models of disease, there is a 
gradual decline in strength, endurance, and nutrition may 
not cause patients to seek medical attention and it often is 
attributed to old age [10]. 
Most of the physicians identify frailty with disability and/
or multi-comorbidity. Fried et al. examined the similarities 
and di#erences between those three factors. While there was 
a 21.5% overlap between the three categories, many more 
people were categorised into just one category or a mix of two 
categories. Only 6% of frail population was disabled (dened 
as being dependent in one or more activities of daily living), 
46% had comorbidity (dened as the presence of 2 or more 
comorbid diseases), but – most importantly – 27% of frail 
population had neither poor function nor comorbidity [12]. 
Frailty is di#erent conceptually from ageing, disability and co-
-morbidity, although it is related to these factors. Its prevalence 
increases with age, however, it occurs independently from 
chronological age [12].
The concept of frailty is still debatable and at present 
there are two principal models of it: the phenotype model 
described by Fried et al. [12] and the cumulative decit mo-
del proposed originally by Rockwood [13]. The rst model, 
widely used (though it has not been validated in older cancer 
patients), is based on the concept that a clinical syndrome 
driven by age-related biologic changes that drive physical 
characteristics of frailty and eventually, adverse outcomes. 
The frailty phenotype, introduced by Fried et al., was dened 
as meeting three or more of the following criteria: uninten-
tional weight loss, self-reported exhaustion, slow walking 
speed, weak grip strength, and low physical activity level 
[12]. In turn, the basis of the decit model is the accumula-
tion of medical, functional, cognitive and social decits that 
can be assessed using Geriatric Assessment and allowing to 
quantitatively summarize vulnerability. The research con-
ducted in our centre showed that the model based on the 
accumulation of decits had the highest predictive power in 
the preoperative evaluation of older patients with cancer. The 
sum of tools, not individual results, was an independent risk 
factor for 30-day mortality and postoperative complications. 
In turn, the number and type of incorporated instruments 
had a great in"uence on the prevalence of frailty and on ade-
quate surgical risk assessment [14–15]. At present, we have 
good evidence that preoperative identication of frailty can 
forecast areas of vulnerability, treatment outcome (including 
morbidity and mortality), length of hospitalization and need 
for discharge to a skilled nursing facility. This knowledge 
allows for the tailored approach improving the treatment 
outcome and avoiding unnecessary harm, particularly to 
frail older patients. 
Conclusions
Frailty is not a disease; it is a concept, unifying the care of older 
patients and directing attention away from organ-specic 
diagnoses towards a more holistic viewpoint of the patient. 
At present, there is no consensus on an operational denition 
of frailty which di#ers among authors and studies. However, 
there is more than good evidence that overtreatment in the 
frail patient can lead to unacceptable outcomes with high 
mortality or persistent disability. Moreover, in this population 
quality of life, functional decline and toxicity of the treatment 
is often much more important than prolonging of life alone. 
Therefore, identication of frailty should be obligatory before 
the beginning of the oncologic treatment.
This mini-review is the rst part of the series, prepared 
by the Oncogeriatric Section of the Polish Society of Surgical 
Oncology, aiming the dissemination of knowledge on diagno-
stic and high-quality treatment of older patient with cancer.
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